1,721,260 research outputs found
New-Generation Hormone Therapies in Nonmetastatic Castration-Resistant Prostate Cancer: Why, Who, When
Full text linkN/
"La causa dei lumi e della libertà". Itinerario filosofico, storico ed archivistico tra gli autografi - editi ed inediti - di Carlo Cattaneo presenti nell'Archivio Bersellini del Centro Internazonale Insubrico
No full textCircolazione delle idee e immagine della ‘nuova scienza’ nella biblioteca e nel carteggio di Bartolomeo Corte (1666-1738)
No full textNeoadjuvant treatment of HER2 and hormone-receptor positive breast cancer - Moving beyond pathological complete response.
No full textThe combination of bevacizumab with chemotherapy is more beneficial in the metastatic setting rather than in the adjuvant setting for the treatment of HER2-negative breast cancer—a commentary on the E5103 randomized phase III clinical study
Full text linkN/
Optimal primary end point in Phase II trials of immune checkpoint inhibitors for advanced solid cancers: An evolving issue
Full text linkN/
Role of the IGF-1 Axis in Overcoming Resistance in Breast Cancer
Full text linkOver the last two decades, many studies have demonstrated that the insulin-like growth factor-1 (IGF-1) is involved in a number of patho-physiological processes, as well as in the development of different types of solid tumors, including breast cancer (BC). Preclinical and clinical data showed that IGF-1 receptor (R) is overexpressed and hyper-phosphorylated in several subtypes of BCs. The central implications of this pathway in tumor cell proliferation and metastasis make it an important therapeutic target. Moreover, the IGF-1 axis has shown strong interconnection with estrogen regulation and endocrine therapy, suggesting a possible solution to anti-estrogen resistance. IGF-1R might also interfere with other pivotal therapeutic strategies, such as anti HER2 treatments and mTOR inhibitors; several clinical trials are ongoing evaluating the role of IGF-1R inhibition in modulating resistance mechanisms to target therapies. Our aim is to offer an overview of the most recent and significant field of application of IGF-1 inhibitors and relevant therapeutic strategies, weighing their possible future impact on clinical practice
Enzalutamide in prostate cancer after chemotherapy.
Full text linkIn the randomized trial reported
by Scher et al. (Sept. 27 issue),1 the administration
of enzalutamide, an androgen-receptor–signaling
inhibitor, was associated with an increased incidence
of headache, as compared with placebo, in
patients with castration-resistant prostate cancer.
Androgens are implicated in the pathogenesis of
migraine; thus, it is important to understand
whether the headache associated with enzalutamide
could be classified as migraine. Moreover,
a deeper understanding of the pathophysiology
of this side effect is clinically relevant, since a
relationship between migraine and the presence
of either hot flashes or seizures has been described
previously.2,3 Migraine and epilepsy have
pathophysiological characteristics in common,3
so patients who have migraine during enzalutamide
therapy may be at increased risk for seizures.
Notably, headache was not reported as a
clinically relevant symptom in patients with castration-
resistant prostate cancer who received
abiraterone,
4 a drug that deeply reduces circulating
androgen levels. Abiraterone was administered
in association with prednisone, and glucocorticoids
are efficacious in preventing migraine.5 It
would be interesting to know whether glucocorticoids
were used in the management of enzalutamide-
induced headache and whether they
were effective
- …
